Current Duke Appointments & Affiliations
Associate Professor of Medicine
·
2024 - Present
Medicine, Hematologic Malignancies and Cellular Therapy,
Medicine
Member of the Duke Cancer Institute
·
2023 - Present
Duke Cancer Institute,
Institutes and Centers
Recent Scholarly Works
Single-agent mosunetuzumab in older or unfit patients with previously untreated DLBCL: results of a phase 1/2 trial
Journal article Blood Neoplasia · August 1, 2026 Full text CiteInfectious Complications of CD19-targeted Chimeric Antigen Receptor T-cell Therapy: a Multicenter Cohort Study.
Journal article Open Forum Infect Dis · July 2026 BACKGROUND: Our understanding of the epidemiology of and risk factors for postchimeric antigen receptor T-cell therapy (CART) infections is largely based on data from single-center studies with small sample sizes. METHODS: This is a multicenter, cohort stu ... Full text Link to item CiteRespiratory Viral Infections Following CD19 CAR T-Cell Therapy.
Journal article J Med Virol · May 2026 Respiratory viral infections (RVI) are an important infectious complication after chimeric antigen receptor (CAR) T-cell therapy. However, the epidemiology of RVI following CAR T-cell therapy and their risk factors are not well defined. To describe the inc ... Full text Link to item CiteRecent Grants
A Phase 2/3 randomized, open label study of MK 1045 in combination with rituximab in participants with 1L follicular lymphoma
Clinical TrialPrincipal Investigator · Awarded by Merck Sharp & Dohme LLC · 2026 - 2031A Prospective, Observational, Long-term Follow-up Study for Subjects who Previously Received Zamtocabtagene Autoleucel in a United States Miltenyi Biomedicine-Sponsored Clinical Study
Clinical TrialPrincipal Investigator · Awarded by Miltenyi Biomedicine · 2025 - 2030Multicenter, Open Label, Phase 3 Study of Tabelecleucel for Solid Organ Transplant Subjects with Epstein-Barr Virus Associated Post-Transplant Lymphoproliferative Disease after Failure of Rituximab or Roituximab and Chemotherapy
Clinical TrialPrincipal Investigator · Awarded by Atara Biotherapeutics, Inc. · 2020 - 2030View All Grants
Education
Duke University ·
2006
M.D.